Director Ossipow details SOPHiA GENETICS (SOPH) share, RSU and option holdings

Rhea-AI Filing Summary

SOPHiA GENETICS SA director Vincent Ossipow filed an initial ownership report showing 503,136 ordinary shares held directly, including 33,784 shares to be delivered under a restricted share unit award that vests at the next annual shareholder meeting.

He also holds fully vested, exercisable share options over 60,000 ordinary shares at an exercise price of $6.31 expiring on January 28, 2031, and options over 49,751 ordinary shares at $3.04 expiring on June 18, 2035.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ossipow Vincent

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	503,136(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	01/28/2031	Ordinary Shares	60,000	$6.31	D
Share Option (Right to Buy)	(3)	06/18/2035	Ordinary Shares	49,751	$3.04	D

Explanation of Responses:

1. Includes 33,784 ordinary shares to be delivered in settlement of a restricted share unit award ("RSU"). Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.

2. The share options are fully vested and exercisable.

3. The share options were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-fact for Vincent Ossipow	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What shareholdings does Vincent Ossipow report in SOPHiA GENETICS (SOPH)?

Vincent Ossipow reports direct ownership of 503,136 ordinary shares of SOPHiA GENETICS SA. This total includes shares already held plus those tied to equity awards, giving investors a clear view of his current equity exposure as a company director.

What stock options does Vincent Ossipow hold in SOPHiA GENETICS (SOPH)?

He holds fully vested share options over 60,000 ordinary shares at $6.31 expiring January 28, 2031, and options over 49,751 ordinary shares at $3.04 expiring June 18, 2035. These options can be exercised into ordinary shares before their expiration dates.

How many RSUs does Vincent Ossipow have in SOPHiA GENETICS (SOPH)?

The filing notes 33,784 ordinary shares will be delivered upon settlement of a restricted share unit award. Each RSU represents one ordinary share, vesting in full at the issuer’s next scheduled annual meeting of shareholders, subject to his continued service.

When do Vincent Ossipow’s SOPHiA GENETICS (SOPH) RSUs vest?

The restricted share units vest 100% as of the date of SOPHiA GENETICS’ next scheduled annual meeting of shareholders. Vesting is conditioned on Ossipow’s continued service with the company through that meeting, after which the RSUs settle into ordinary shares.

Are Vincent Ossipow’s SOPHiA GENETICS share options already vested?

Yes. The filing states that the share options are fully vested and exercisable. This means Ossipow can choose to exercise these options for ordinary shares at their stated exercise prices any time before their respective expiration dates.

What does this Form 3 filing indicate about SOPHiA GENETICS (SOPH) insider ownership?

This Form 3 discloses Vincent Ossipow’s initial beneficial ownership as a director, detailing his ordinary shares, RSUs, and stock options. It establishes a baseline of his equity stake, but does not report any new purchases or sales.